Related Experiment Video
Updated: Jan 29, 2026
08:11
Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics
Published on: March 26, 2018
8.8K
Immunotherapy in extensive small cell lung cancer.
Vaibhav Verma1,2, Geeti Sharma3, Abhijai Singh1
11Mon Health Medical Center, Morgantown, WV USA.
Experimental Hematology & Oncology
|February 12, 2019
Summary
Immunotherapy, including checkpoint inhibitors, shows promise for extensive small cell lung cancer. Recent trials demonstrate significant survival benefits and impressive response rates in both treatment-naive and relapsed patients.
Area of Science:
- Oncology
- Immunology
- Pulmonology
Background:
- Small cell lung cancer (SCLC) is distinct from non-small cell lung cancer (NSCLC), characterized by rapid growth and early metastasis.
- SCLC exhibits neuroendocrine features and a unique response pattern to cytotoxic treatments, often developing resistance.
- Immune checkpoint inhibitors target the PD-1/PD-L1 and CTLA-4 pathways to overcome tumor-induced immune suppression.
Purpose of the Study:
- To review recent advancements in immunotherapy for extensive small cell lung cancer (ES-SCLC).
- To summarize the current landscape of immunotherapy in non-small cell lung cancer (NSCLC).
- To outline investigational approaches in SCLC immunotherapy.
Main Methods:
- Review of recent clinical trials and studies on immunotherapy in SCLC and NSCLC.
- Analysis of data from key trials such as CheckMate 032 and IMpower 133.
- Summary of immune checkpoint inhibitor mechanisms and their application in lung cancer.
Main Results:
- CheckMate 032 showed impressive response rates with Nivolumab and Nivolumab/Ipilimumab in relapsed SCLC.
- IMpower 133 demonstrated a significant survival benefit with Atezolizumab plus chemotherapy in treatment-naive ES-SCLC.
- Immunotherapy offers a new avenue with potentially severe but less frequent immune-related adverse effects compared to chemotherapy.
Conclusions:
- Immunotherapy, particularly checkpoint inhibitors, has emerged as a significant treatment modality for extensive small cell lung cancer.
- Ongoing studies and investigational approaches continue to expand the role of immunotherapy in SCLC treatment.
- Understanding the immune landscape of both SCLC and NSCLC is crucial for optimizing therapeutic strategies.
Related Concept Videos
01:27Tumor Immunotherapy
1.9K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.9K
01:47Lung Capacity
56.3K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.3K
01:35Cancer Cell Migration through Invadopodia
3.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.3K
02:53Adaptive Mechanisms in Cancer Cells
7.1K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.1K
01:13Pleura of the Lungs
7.1K
The lungs are nestled in a cavity, shielded by the pleura. The pleura, a form of serous membrane, wraps around each lung. This membrane arrangement consists of two layers: the visceral and parietal pleurae. The visceral pleura lines the surface of the lungIn contrast, the parietal pleura is the outer layer and contacts to the thoracic wall, the mediastinum, and the diaphragm. The hilum is the point of connection between the visceral and parietal layers. The space between the parietal and...
7.1K
02:40Cancer Stem Cells and Tumor Maintenance
6.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.0K